Ameriprise
TXG icon

Ameriprise’s 10x Genomics TXG Stock Holding History

Ameriprise’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.04M Sell
235,766
-96,758
-29% -$2.54M ﹤0.01% 2122
2026
Q1 		$7.06M Sell
332,524
-50,645
-13% -$1.01M ﹤0.01% 2197
2025
Q4 		$6.25M Buy
383,169
+41,028
+12% +$620K ﹤0.01% 2273
2025
Q3 		$4M Sell
342,141
-101,608
-23% -$1.32M ﹤0.01% 2596
2025
Q2 		$5.14M Buy
443,749
+313,160
+240% +$2.85M ﹤0.01% 2343
2025
Q1 		$1.14M Buy
+130,589
New +$1.65M ﹤0.01% 3159
2024
Q4 		– Sell
-77,371
Closed -$1.75M – 4166
2024
Q3 		$1.75M Buy
77,371
+16,810
+28% +$348K ﹤0.01% 2978
2024
Q2 		$1.18M Sell
60,561
-405,793
-87% -$10.6M ﹤0.01% 3093
2024
Q1 		$17.5M Sell
466,354
-48,987
-10% -$2.15M ﹤0.01% 1388
2023
Q4 		$28.8M Buy
515,341
+500,802
+3,445% +$21.8M 0.01% 1063
2023
Q3 		$600K Sell
14,539
-15,845
-52% -$824K ﹤0.01% 3334
2023
Q2 		$1.7M Sell
30,384
-22,736
-43% -$1.23M ﹤0.01% 2957
2023
Q1 		$2.96M Sell
53,120
-5,704
-10% -$266K ﹤0.01% 2648
2022
Q4 		$2.14M Buy
58,824
+6,057
+11% +$198K ﹤0.01% 2776
2022
Q3 		$1.5M Sell
52,767
-4,747
-8% -$181K ﹤0.01% 2912
2022
Q2 		$2.6M Sell
57,514
-1,578,382
-96% -$81.9M ﹤0.01% 2710
2022
Q1 		$124M Buy
1,635,896
+40,627
+3% +$3.55M 0.04% 451
2021
Q4 		$238M Buy
1,595,269
+520,671
+48% +$79.8M 0.07% 309
2021
Q3 		$156M Sell
1,074,598
-255,124
-19% -$43.8M 0.05% 392
2021
Q2 		$260M Sell
1,329,722
-79,485
-6% -$14.4M 0.08% 260
2021
Q1 		$255M Buy
1,409,207
+37,573
+3% +$6.49M 0.08% 239
2020
Q4 		$194M Buy
1,371,634
+606,538
+79% +$88M 0.07% 294
2020
Q3 		$95.4M Buy
765,096
+224,219
+41% +$23.5M 0.04% 434
2020
Q2 		$48.3M Buy
540,877
+347,974
+180% +$27.1M 0.02% 636
2020
Q1 		$12M Buy
192,903
+176,093
+1,048% +$13.7M 0.01% 1257
2019
Q4 		$1.28M Buy
16,810
+6,086
+57% +$366K ﹤0.01% 2951
2019
Q3 		$540K Buy
+10,724
New +$593K ﹤0.01% 3276

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise's TXG Position: Q2 2026 in Review

Ameriprise reduced its 10x Genomics (TXG) stake by 29% in Q2 2026, selling an estimated $2.54M and leaving 235,766 shares worth $9.04M. The position accounts for ﹤0.01% of the portfolio, ranked #2122.

Ameriprise first reported a position in TXG in Q3 2019 and has held it in 27 quarters since. The position peaked at $260M in Q2 2021. 391 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Ameriprise held 235,766 shares of 10x Genomics worth $9.04M as of Q2 2026.
  • Ameriprise sold 96,758 10x Genomics shares in Q2 2026, an estimated $2.54M.
  • 10x Genomics made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #2122 holding.
  • Ameriprise first reported a position in 10x Genomics in Q3 2019 and has held it in 27 quarters since.
  • Ameriprise's 10x Genomics position peaked at $260M in Q2 2021.
  • 391 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.